AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
Log in

NASDAQ:MACKMerrimack Pharmaceuticals Stock Price, Forecast & News

$3.43
-0.07 (-2.00 %)
(As of 06/4/2020 01:50 PM ET)
Add
Compare
Today's Range
$3.40
Now: $3.43
$3.47
50-Day Range
$3.33
MA: $3.56
$3.88
52-Week Range
$1.49
Now: $3.43
$7.09
Volume94 shs
Average Volume19,337 shs
Market Capitalization$45.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Read More
Merrimack Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.30 per share

Profitability

Net Income$-17,330,000.00

Miscellaneous

Employees27
Market Cap$45.89 million
Next Earnings Date7/15/2020 (Estimated)
OptionableOptionable

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

How has Merrimack Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Merrimack Pharmaceuticals' stock was trading at $2.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MACK shares have increased by 24.3% and is now trading at $3.43. View which stocks have been most impacted by Coronavirus.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 15th 2020. View our earnings forecast for Merrimack Pharmaceuticals.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported $0.02 EPS for the quarter. View Merrimack Pharmaceuticals' earnings history.

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals announced a -- dividend on Wednesday, December 4th. Shareholders of record on Monday, December 16th will be paid a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date of this dividend is Friday, December 13th. View Merrimack Pharmaceuticals' dividend history.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals's stock reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

Media headlines about MACK stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutMerrimack Pharmaceuticals.

Who are some of Merrimack Pharmaceuticals' key competitors?

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC), Exelixis (EXEL) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the following people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 56)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Sepio Capital LLC (2.64%). Company insiders that own Merrimack Pharmaceuticals stock include Eric Andersen, Fund Lp 22Nw, Jason Aryeh, Jfl Capital Management, Llc, Lp 22Nw and Noah G Levy. View institutional ownership trends for Merrimack Pharmaceuticals.

Which institutional investors are selling Merrimack Pharmaceuticals stock?

MACK stock was sold by a variety of institutional investors in the last quarter, including Sepio Capital LLC. View insider buying and selling activity for Merrimack Pharmaceuticals.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $3.43.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $45.89 million. Merrimack Pharmaceuticals employs 27 workers across the globe.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.